Use of synthetic derivatives to determine the minimal active structure of cytokine-inducing lipoteichoic acid

Clinical and Vaccine Immunology

Volumn 14, Issue 12, 2007, Pages 1629-1633

  Deininger, Susanne ^a   Figueroa Perez, Ignacio ^a   Sigel, Stefanie ^a   Stadelmaier, Andreas ^a   Schmidt, Richard R ^a   Hartung, Thomas ^a,b   Von Aulock, Sonja ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYTOKINE; DEXTRO ALANINE; GLYCEROPHOSPHATE; INTERLEUKIN 8; LIPOTEICHOIC ACID; TOLL LIKE RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SYNTHESIS;

ANIMALS; CELL LINE; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KIDNEY; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, KNOCKOUT; MODELS, CHEMICAL; STAPHYLOCOCCUS AUREUS; STATISTICS AS TOPIC; TEICHOIC ACIDS; TOLL-LIKE RECEPTOR 2; TRANSFECTION;

EID: 38049086674     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00007-07     Document Type: Article

References (17)

1. Deininger, S., A. Stadelmaier, S. Von Aulock, S. Morath, R. R. Schmidt, and T. Hartung. 2003. Definition of structural prerequisites for lipoteichoic acid-inducible cytokine induction by synthetic derivatives. J. Immunol. 170:4134-4138.
2. Figueroa-Perez, I., A. Stadelmaier, S. Deininger, S. V. Aulock, T. Hartung, and R. R. Schmidt. 2006. Synthesis of Staphylococcus aureus lipoteichoic acid derivatives for determining the minimal structural requirements for cytokine induction. Carbohydr. Res. 341:2901-2911.
3. Grangette, C., S. Nutten, E. Palumbo, S. Morath, C. Hermann, J. Dewulf, B. Pot, T. Hartung, P. Hols, and A. Mercenier. 2005. Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc. Natl. Acad. Sci. USA 102:10321-10326.
4. Henneke, P., S. Morath, S. Uematsu, S. Weichert, M. Pfitzenmaier, O. Takeuchi, A. Muller, C. Poyart, S. Akira, R. Berner, G. Teti, A. Geyer, T. Hartung, P. Trieu-Cuot, D. L. Kasper, and D. T. Golenbock. 2005. Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J. Immunol. 174:6449-6455.
5. Hermann, C., I. Spreitzer, N. W. Schroder, S. Morath, M. D. Lehner, W. Fischer, C. Schutt, R. R. Schumann, and T. Hartung. 2002. Cytokine induction by purified lipoteichoic acids from various bacterial species - role of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-gamma release. Eur. J. Immunol. 32:541-551.
6. Hoebe, K., P. Georgel, S. Rutschmann, X. Du, S. Mudd, K. Crozat, S. Sovath, L. Shamel, T. Hartung, U. Zahringer, and B. Beutler. 2005. CD36 is a sensor of diacylglycerides. Nature 433:523-527.
7. Lehner, M. D., S. Morath, K. S. Michelsen, K. R. Schumann, and T. Hartung. 2001. Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J. Immunol. 166:5161-5167.
8. Morath, S., A. Geyer, and T. Hartung. 2001. Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J. Exp. Med. 193:393-397.
9. Morath, S., A. Geyer, I. Spreitzer, C. Hermann, and T. Hartung. 2002. Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect. Immun. 70:938-944.
10. Morath, S., A. Stadelmaier, A. Geyer, R. R. Schmidt, and T. Hartung. 2002. Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J. Exp. Med. 195:1635-1640.
11. Morath, S., S. von Aulock, and T. Hartung. 2005. Structure/function relationships of lipoteichoic acids. J. Endotoxin Res. 11:348-356.
12. Nagai, Y., S. Akashi, M. Nagafuku, M. Ogata, Y. Iwakura, S. Akira, T. Kitamura, A. Kosugi, M. Kimoto, and K. Miyake. 2002. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat. Immunol. 3:667-672.
13. Schroder, N. W., S. Morath, C. Alexander, L. Hamann, T. Hartung, U. Zahringer, U. B. Gobel, J. R. Weber, and R. R. Schumann. 2003. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 278:15587-15594.
14. Shimazu, R., S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K. Miyake, and M. Kimoto. 1999. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189:1777-1782.
15. Stadelmaier, A., S. Morath, T. Hartung, and R. R. Schmidt. 2003. Synthesis of the first fully active lipoteichoic acid. Angew. Chem. Int. Ed. Engl. 42:916-920.
16. Westphal, O., O. Luderitz, and W. Keiderling. 1952. Effects of bacterial toxins; biochemical analysis of inflammation. Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. 1 Orig. 158:152-160. (In German.)
17. Wright, S. D., R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C. Mathison. 1990. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249:1431-1433.